EndoPulse System for Endoscopic Ultrasound-Guided Therapy of Pancreatic Carcinoma

用于内镜超声引导治疗胰腺癌的 EndoPulse 系统

基本信息

批准号：
8252023
负责人：
RICHARD Lee NUCCITELLI
金额：
$ 101.91万
依托单位：
BIOELECTROMED CORPORATION
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-09-01 至 2014-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8252023
关键词：
Ablation Academic Medical Centers Accounting Aftercare Apoptosis Cancer Death Rates Clinical Clinical Trials Contracts Data Devices Diagnosis Dimensions Disease Electrodes Enrollment Evaluation Family suidae Gastroenterologist Gastroscopes Goals Grant Human In Vitro Incidence Induction of Apoptosis Joints Kidney Lead Lesion Life Liver Malignant neoplasm of pancreas Manufacturer Name Medical Device Medical Device Safety Medical center Modeling Modification Monitor Morbidity - disease rate Operative Surgical Procedures Pancreas Pancreatic carcinoma Patients Physiologic pulse Principal Investigator Rattus Research Safety Shapes Side Skin Cancer Solid Neoplasm Sterility Stomach System Technology Testing Tissues Ultrasonography Work Xenograft Model biomaterial compatibility design effective therapy electric field improved instrument lymph nodes minimally invasive mortality nanosecond neoplastic cell pancreatic neoplasm prototype research clinical testing response subcutaneous tumor tumor eradication verification and validation voltage

项目摘要

DESCRIPTION (provided by applicant): BioElectroMed is developing a new medical device called the EndoPulse" that works in conjunction with an echoendoscope to deliver nanosecond pulsed electric field therapy to treat pancreatic carcinoma as well as lesions in the kidney and liver. The EndoPulse" is designed to penetrate through the stomach wall into a pancreatic carcinoma before extending an electrode array on both sides of the tumor. We are also developing a high voltage model of the PulseCure" nanosecond pulse generator that can generate 30 kV/cm between the two electrode arrays, exposing the entire tumor to this field strength. We have determined that the application of 500 pulses 100 ns long and 30 kV/cm in amplitude triggers apoptosis in all the human tumor cells between the electrodes and causes them to self-destruct within two weeks. We propose to complete the design and testing of both the EndoPulse" and PulseCure" prototypes and have the final versions manufactured under GMP for use in human clinical trials. These two instruments will then be used to ablate small regions of pancreas in pigs to demonstrate safety and efficacy prior to submitting the application to the FDA for an Investigational Device Exemption (IDE) required for the clinical trial. Once the IDE is granted, we will conduct a six-patient feasibility clinical trial at Stanford University Medical Center with Drs. Ann Chen and Subhas Banerjee acting as Co-Principal Investigators of this trial. These two gastroenterologists receive 3-4 patients per month with non-resectable pancreatic carcinomas for which there is currently no effective therapy. If the PulseCure"-EndoPulse" system can reliably ablate pancreatic carcinomas, it would offer the first effective, non-surgical therapy for pancreatic cancer that could extend the lives of tens of thousands of patients each year. PUBLIC HEALTH RELEVANCE: This research will develop a breakthrough, minimally invasive approach to the treatment of pancreatic tumors for which current treatment options are poor and costly. This new medical device called the EndoPulse is readily extendable to treat other focal internal lesions especially in the liver, kidney and lymph nodes. The EndoPulse is guided to the internal tumor by ultrasound imaging in an echoendoscope and applies ultrashort electrical pulses that cause the tumor cells to self-destruct.

描述（由申请人提供）：BioElectroMed 正在开发一种名为 EndoPulse 的新型医疗设备，该设备与回声内窥镜配合使用，可提供纳秒脉冲电场治疗，以治疗胰腺癌以及肾脏和肝脏病变。EndoPulse 是旨在穿透胃壁进入胰腺癌，然后在肿瘤两侧延伸电极阵列。我们还正在开发 PulseCure 纳秒脉冲发生器的高压模型，它可以在两个电极阵列之间产生 30 kV/cm 的电压，使整个肿瘤暴露在这种场强下。我们已经确定，应用 500 个 100 ns 长的脉冲和30 kV/cm 的振幅会触发电极之间所有人类肿瘤细胞的凋亡，并导致它们在两周内自毁。我们建议完成 EndoPulse 和 EndoPulse 的设计和测试。 PulseCure”原型，并根据 GMP 生产最终版本，用于人体临床试验。然后，这两种仪器将用于消融猪的小部分胰腺，以证明安全性和有效性，然后再向 FDA 提交研究设备申请临床试验所需的豁免 (IDE) 一旦获得 IDE，我们将在斯坦福大学医学中心进行一项由 Ann Chen 博士和 Subhas Banerjee 博士担任的可行性临床试验。本次试验的联合首席研究员。这两位胃肠病学家每月接收 3-4 名患有不可切除的胰腺癌的患者，目前尚无有效的治疗方法。如果 PulseCure“-EndoPulse”系统能够可靠地消融胰腺癌，它将为胰腺癌提供第一种有效的非手术疗法，每年可以延长数万名患者的生命。公共健康相关性：这项研究将开发一种突破性的微创方法来治疗胰腺肿瘤，目前的治疗方案效果不佳且成本高昂。这种名为 EndoPulse 的新型医疗设备可以轻松扩展以治疗其他局灶性内部病变，尤其是肝脏、肾脏和淋巴结。 EndoPulse 通过回声内窥镜中的超声成像引导至内部肿瘤，并施加超短电脉冲，导致肿瘤细胞自毁。